Methotrax 15 Tablet

About Methotrax 15 Tablet

The tablet Methotrax 15 contains Methotrexate and is made by Delta Pharma Limited. Only a specialist doctor can decide whether it is suitable.

There are 4 brands of Methotrexate listed in Bangladesh. The lowest listed price is Methotrax 2.5 mg Tablet at ৳ 5.00 per unit.

What is Methotrax 15 Tablet?

Made by Delta Pharma Limited, Methotrax 15 is a tablet whose active ingredient is Methotrexate. Methotrexate is used in some cancers, such as gestational choriocarcinoma, breast cancer, and certain types of lymphoma, and in inflammatory conditions like psoriasis and rheumatoid arthritis. The medicine is used in selected neoplastic diseases and some inflammatory conditions, but only under close medical supervision. Whether it suits you is a decision for your doctor.

Uses of Methotrax 15

Only a specialist doctor can decide whether it is suitable. Methotrax 15 is used in the treatment of certain neoplastic diseases, including gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole. It is also used in maintenance therapy with other chemotherapy agents. Ask your doctor whether it is right for your condition.

How to use Methotrax 15

The dose, frequency, and duration are decided by the doctor and must be followed exactly. Methotrax 15 is taken by mouth. Swallow the tablet with water. It is not for self-administration. The doctor decides the dose, how often to take it and how long the course lasts. Do not change the dose or stop early without asking your doctor.

Side effects of Methotrax 15

Because side effects can be serious, regular monitoring by your doctor is important. Methotrexate can cause side effects. Some people may experience more serious effects. Tell your doctor promptly about mouth sores, fever, unusual tiredness, bruising, bleeding or any new symptom. Tell your doctor if any side effect bothers you or does not go away.

Safety and precautions

Elderly patients and those with gastrointestinal ulcers need careful monitoring. Do not take other medicines, including vitamins, without asking your doctor. Methotrexate is not suitable for everyone. Tell your doctor if you have liver or kidney problems, are elderly, or have stomach or bowel ulcers.

Frequently asked questions

What does Methotrax 15 treat?

Only a specialist doctor can decide whether it is suitable. Methotrax 15 is used in the treatment of certain neoplastic diseases, including gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole.

How is Methotrax 15 used?

The dose, frequency, and duration are decided by the doctor and must be followed exactly. Methotrax 15 is taken by mouth.

Can Methotrax 15 cause side effects?

Because side effects can be serious, regular monitoring by your doctor is important. Methotrexate can cause side effects.

Is Methotrax 15 safe for everyone?

Elderly patients and those with gastrointestinal ulcers need careful monitoring. Do not take other medicines, including vitamins, without asking your doctor.

Indications

Neoplastic Diseases: Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or ... Read moreNeoplastic Diseases: Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast  cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.

Psoriasis: Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses.

Rheumatoid Arthritis Including Polyarticular-Course Juvenile Rheumatoid Arthritis: Methotrexate is indicated in the management of selected adults with severe, active, rheumatoid arthritis (ACR criteria), or children with active polyarticular course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.

Pharmacology

Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of p.r.n. nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues

Dosage & Administration

Oral-
  • Choriocarcinoma: 15-30 mg daily for 5 days, repeat after an interval of ≥1 wk for 3-5 courses.
  • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
  • Burkitt's lymphoma: 10-25 mg daily for 4-8 days, repeated after 7-10 days.
  • Psoriasis: 10-25 mg wkly as a single dose, adjust subsequent doses based on response.
  • Rheumatoid arthritis: 7.5 mg once wkly, adjust by response. Not more than 20 mg/wk.
  • Mycosis fungoides: 2.5-10 mg daily to induce remission.
  • Crohn's disease: 12.5-22.5 mg once wkly for up to 1 yr.
Parenteral-
  • Psoriasis: 10-25 mg wkly as a single dose. Adjust subsequent doses based on response. May be given via IV/IM admin.
Intramuscular-
  • Choriocarcinoma: 15-30 mg daily for 5 days. Repeat after at least 1 wk for 3-5 courses. Alternatively, 0.25-1 mg/kg (max: 60 mg) every 48 hr for 4 doses followed by folinic acid rescue, repeat at intervals of 7 days for 4 or more courses.
  • Mycosis fungoides: 50 mg wkly as a single dose or 2 divided doses.
  • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
  • Crohn's disease: 25 mg once wkly for 16 wk. Maintenance: 15 mg wkly.
Intrathecal-
  • Meningeal leukaemia: 12 mg/m2 (max 15 mg) once wkly for 2-3 wk, then once mthly. Alternatively, 200-500 mcg/kg every 2-5 day until CSF cell count is normalised.
Intravenous-
  • Osteosarcoma: Initial recommended dose: 12 g/m2 as a 4-hr infusion, followed by folinic acid, as part of combined therapy. May increase dose to 15 g/m2 in subsequent treatments if initial dosage is insufficient to achieve peak serum methotrexate levels of 454 mcg/mL at the end of the infusion. Methotrexate infusion is administered on postoperative wk 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44 and 45; in combination with other chemotherapy agents. Folinic acid can be given orally, IM or IV inj starting 24 hr after the beginning of the methotrexate infusion. Give via parenteral routes If patient experiences GI toxicity (e.g., nausea, vomiting). Usual dosage of folinic acid: 15 mg every 6 hr for a total of 60 hr or a total of 10 doses.
  • Breast cancer: 10-60 mg/m2 often with cyclophosphamide and fluorouracil.
  • Advanced lymphosarcoma: Up to 30 mg/kg, followed by folinic acid rescue.
  • Acute lymphoblastic leukaemia: Maintenance: 2.5 mg/kg every 14 days.

Interaction

Decreased effectiveness with folic acid and its derivatives.

Contraindications

Severe renal or hepatic impairment, pre-existing profound bone marrow suppression in patients with psoriasis or rheumatoid arthritis, alcoholic liver disease, AIDS, pre-existing blood dyscrasias, pregnancy (in patients with psoriasis or rheumatoid arthritis), breast-feeding.

Side Effects

Ulceration of the mouth and GI disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility.

Pregnancy & Lactation

Pregnancy category X. Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Precautions & Warnings

Hepatic or renal impairment, bone marrow depression, elderly, neonates. Ulcerative disorders of the GI tract. Monitor haematological, renal and hepatic function, and GI toxicity regularly.

Overdose Effects

Nausea, vomiting, alopecia, melena, and renal failure.

Storage Conditions

Store at room temperature (15-25°C).

Alternative brands of Methotrexate

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.